Гіперурикемія — незалежний фактор прогресування хронічної хвороби нирок

M.D. Tronko; M.N. Dolzhenko; S.V. Kushnirenko; V.L. Orlenko; S.V. Potashev; O.O. Shevchuk

doi:10.22141/2307-1257.6.2.2017.102787

Authors

M.D. Tronko Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine State Institution «V.P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine», Kyiv, Ukraine
M.N. Dolzhenko Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine
S.V. Kushnirenko Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine
V.L. Orlenko State Institution «V.P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine», Kyiv, Ukraine
S.V. Potashev Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine
O.O. Shevchuk State Institution «Institute of Urology» of the National Academy of Medical Sciences of Ukraine», Kyiv, Ukraine

DOI:

https://doi.org/10.22141/2307-1257.6.2.2017.102787

Keywords:

hyperuricemia, chronic kidney disease, Urolesan®

Abstract

Objective of the research — to evaluate the efficacy of combined hypouricemic therapy in patients with hyperuricemia, urate nephropathy on the background of concomitant pathology (type 2 diabetes mellitus, hypertension) based on the dynamics of uricemia, uricosuria, the functional state of the kidneys, minimizing and eliminating the risk factors for the progression of chronic kidney disease. Sixty seven patients were involved in the study. Correction of hyperuricemia in patients with urate nephropathy and concomitant pathology (type 2 diabetes mellitus, hypertension) using phytodiuretic agent Urolesan® in combination treatment leads to normalization of metabolic processes, improvement of glomerular filtration rate, and a decrease in the level of albumin excretion.

Downloads

Download data is not yet available.

References

Ivanov DD, Korzh OM. Nefrologіja v prakticі sіmejnogo lіkarja [Nephrology in Practice of Family Physician]. Donetsk: Publisher Zaslzvskyi; 2014. 464 p.

Іvanov DD, Vozіanov SO, Kushnіrenko SV, et al. Metodichnі rekomendacії. Sechokam'jana hvoroba, dismetabolіchna nefropatіja, kristalurіja. [Guidelines. Urolithiasis, dysmetabolic nephropathy, crystalluria]. Kyiv; 2014. 36 p.

Bhole V, de Vera M, Rahman MM, et al. Epidemiology of gout in women: Fifty-two-year follow up of a prospective cohort. Arthritis Rheum. 2010;62(4):1069-76. doi: 10.1002/art.27338.

Bobulescu IA, Moe OW. Renal Transport of Uric Acid: Evolving Concepts and Uncertainties. Adv Chronic Kidney Dis. 2012;19(6):358-71. PMID: 23089270. doi: 10.1053/j.ackd.2012.07.009.

Bose B, Badve SV, Hiremath SS, Boudville N, Brown FG, Cass A, et al. Effects of uric acid — lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2014;29:406-13. doi: 10.1093/ndt/gft378.

Gaffo AL, Roseman JM, Jacobs DR Jr, et al. Serum urate and its relationship with alcoholic beverage intake in men and women: findings from the Coronary Artery Risk Development in Young Adults (CARDIA) cohort. Ann Rheum Dis. 2010 Nov;69(11):1965-70. doi: 10.1136%2Fard.2010.129429.

Giordano C, Karasik O, King-Morris K, Asmar A. Uric Acid as a Marker of Kidney Disease: Review of the Current Literature. Hindawi Publishing Corporation Disease Markers. 2015; 2015. doi: 10.1155/2015/382918.

Jalal DI, Chonchol M, Chen W, Targher G. Uric Acid as a Target of Therapy in CKD. Am J Kidney Dis. 2013;61(1):134-46. doi: 10.1053/j.ajkd.2012.07.021.

Johnson RJ, Nakagawa T, Jalal D, Sánchez-Lozada LG, Kang DH, Ritz E. Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant. 2013 Sep;28(9):2221-8. doi: 10.1093/ndt/gft029.

Kim IY, Lee DW, Lee SB, Kwak IS. The Role of Uric Acid in Kidney Fibrosis: Experimental Evidences for the Causal Relationship. BioMed Research International. 2014;2014. doi: 10.1155/2014/638732.

KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney international supplements. 2013;3(1):73.

Krishnan E, Pandya BJ, Chung L, Dabbous O. Hyperuricemia and the risk for subclinical coronary atherosclerosis — data from a prospective observational cohort study. Arthritis Res Ther. 2011 Apr 18;13(2):66. PMID: 21501486. doi: 10.1186/ar3322.

Lottmann K, Chen X, Schadlich PK. Association between gout and all-cause as well as cardiovascular mortality: a systematic review. Curr Rheumatol Rep. 2012 Apr;14(2):195-203. PMID: 22350606. doi: 10.1007/s11926-011-0234-2.

Nacak H, van Diepen M, Qureshi AR, Carrero JJ, Stijnen T, Dekker FW, Evans M. Uric acid is not associated with decline in renal function or time to renal replacement therapy initiation in a referred cohort of patients with Stage III, IV and V chronic kidney disease. Nephrol Dial Transplant. 2015;30(12):2039-45. PMID: 26185050. doi: 10/1093/ndt/gfv225.